Trends in antidiabetic prescription patterns in Japan from 2005 to 2011: Impact of the Introduction of Dipeptidyl Peptidase-4 Inhibitors

International Heart Journal

Volumn 54, Issue 2, 2013, Pages 93-97

  Kohro, Takahide ^a   Yamazaki, Tsutomu ^b   Sato, Hiroki ^c   Harada, Kenji ^c   Ohe, Kazuhiko ^c   Komuro, Issei ^a   Nagai, Ryozo ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Antidiabetics; Clinical guidelines; Dipeptidyl peptidase 4 inhibitor; Prescription trends

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INSULIN; SULFONYLUREA;

ADULT; ARTICLE; AWARENESS; DRUG MECHANISM; DRUG SAFETY; EUROPE; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; TREND STUDY; UNITED STATES;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84875911172     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.54.93     Document Type: Article

References (32)

1. Efanova IB, Zaitsev SV, Zhivotovsky B, et al. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J Biol Chem 1998; 273: 33501-7.
2. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90: 501-6.
3. Del Guerra S, Marselli L, Lupi R, et al. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications 2005; 19: 60-4.
4. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43.
5. Marchetti P, Del Guerra S, Marselli L, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 2004; 89: 5535-41.
6. Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002; 51 Suppl 1: S134-7.
7. Patanè G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 2000; 49: 735-40.
8. Lupi R, Del Guerra S, Tellini C, et al. The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur J Pharmacol 1999; 364: 205-9.
9. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-65.
10. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-9.
11. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
12. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-22.
13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
14. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.
15. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-39.
16. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
17. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
18. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-72.
19. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
20. Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol 2010; 20: 413-9.
21. Japan Medical Data Center. Available at: http://www.jmdc.co.jp/Accessed December 18, 2012.
22. Baviera M, Monesi L, Marzona I, et al. Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: a large population-based study. Diabetes Res Clin Pract 2011; 93: 123-30.
23. Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM. Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf 2009; 18: 973-6.
24. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008; 168: 2088-94.
25. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004; 66 Suppl 1: S37-43. (Review)
26. Hoogwerf BJ. Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD. Cleve Clin J Med 2008; 75: 729-37. (Review)
27. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011; 11: 115-28. (Review)
28. Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf 2009; 8: 573-84. (Review)
29. Bodmer M, Meier C, Kraenzlin ME, Meier CR. Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf 2009; 32: 539-47. (Review)
30. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med 2002; 19: 279-84.
31. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twicedaily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002; 95: 68-71.
32. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012; 344: e1369.